InnoCare Pharma’s Promising Phase I Study on ICP-248 for B-cell Malignancies

InnoCare Pharma Ltd. ((HK:9969)) announced an update on their ongoing clinical study.

InnoCare Pharma Ltd. is conducting a Phase I clinical study titled ‘A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Patients With Mature B-cell Malignancies.’ The study aims to assess the safety and effectiveness of ICP-248, a novel drug, either alone or in combination with anti-CD20 monoclonal antibodies, for treating mature B-cell malignancies. This research is significant as it explores new treatment avenues for these challenging cancer types.

The intervention involves testing ICP-248, an oral drug administered daily at escalating doses, both as a standalone treatment and in combination with monoclonal antibodies like Obinutuzumab and Rituximab. These combinations aim to enhance the therapeutic effects against B-cell malignancies.

The study follows a non-randomized, single-group assignment model with no masking, focusing primarily on treatment. Participants are divided into cohorts receiving varying combinations and dosages of ICP-248 and monoclonal antibodies over 28-day cycles.

The study began on April 2, 2024, with the latest update submitted on June 17, 2025. These dates are crucial as they indicate the study’s progress and the timeline for potential data release, which could influence market dynamics.

InnoCare Pharma’s ongoing study could impact its stock performance positively if results indicate promising outcomes, potentially boosting investor confidence. The study’s progress is also relevant in the context of competition within the pharmaceutical industry, where advancements in cancer treatment are highly valued.

The study is currently recruiting, with further details available on the ClinicalTrials portal.